Abstracts tagged "reactive arthritis and spondylarthritis"

Abstract Number: 1217 • 2018 ACR/ARHP Annual Meeting
Trend of Frequency and Outcome of Reactive Arthritis in Japanese Patients with Bladder Cancer Following Intravesical BCG Therapy over the Last 20 Years
Satoshi Inotani¹ and Yoshinori Taniguchi², ¹Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi Medical School, Kochi, Japan, ²Endocrinology, Metabolism,Nephrology and Rheumatology, Kochi University, Kochi, Japan
Background/Purpose: Reactive arthritis (ReA) is a sterile arthritis occurring in a genetically predisposed individual, secondary to an extra-articular infection, usually of the gastrointestinal or genitourinary…
Abstract Number: 1574 • 2017 ACR/ARHP Annual Meeting
Gut Microbiota Perturbations in Reactive Arthritis
Julia Manasson¹, Nan Shen², Helga R. Garcia Ferrer^3,4, Carles Ubeda⁵, Isa Iraheta^3,4, Adriana Heguy⁶, Joan M. Von Feldt⁷, Luis R. Espinoza⁸, Abraham Garcia Kutzbach⁹, Leopoldo N. Segal¹⁰, Alexis Ogdie¹¹, Jose C. Clemente² and Jose U. Scher¹², ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Department of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, ³Guatemalan Association against Rheumatic Diseases (AGAR), Guatemala City, Guatemala, ⁴Universidad Francisco Marroquin, Guatemala City, Guatemala, ⁵Institute for Research in Public Health, Valencia, Spain, ⁶Department of Pathology, New York University Genome Technology Center, New York University School of Medicine, New York, NY, ⁷Hospital of the University of Pennsylvania, Philadelphia, PA, ⁸Internal Medicine, LSU Health Sciences Center, New Orleans, LA, ⁹Internal Medicine, Rheumatology Unit (AGAR), Francisco Marroquin University, School of Medicine, Guatemala City, Guatemala, ¹⁰Department of Medicine, Division of Pulmonary and Critical Care, New York University School of Medicine, New York City, NY, ¹¹Division of Rheumatology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ¹²New York University School of Medicine, New York, NY
Background/Purpose: Reactive arthritis (ReA) is an inflammatory condition occurring several weeks after gastrointestinal (GI) or genitourinary (GU) infections. HLA-B27 positivity is considered a risk factor,…
Abstract Number: 674 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics of Japanese Patients with Reactive Arthritis Induced By Intravesical BCG Therapy for Bladder Cancer: A 19 Years Two-Center Retrospective Study
Hirofumi Nishikawa¹, Yoshinori Taniguchi¹, Takashi Karashima², Tetsushi Aita³, Susumu Nishiyama³, Yasuhiko Yoshinaga³, Yoshitaka Kumon⁴, Yoshiko Shimamura¹, Kosuke Inoue¹, Taro Horino¹, Taro Shuin² and Yoshio Terada¹, ¹Kochi University, Nankoku, Japan, ²Urology, Kochi University, Nankoku, Japan, ³Kurashiki Medical Center, Kurashiki, Japan, ⁴Chikamori Hospital, Kochi, Japan
Background/Purpose: Intravesical instillation of BCG is used as an effective immunotherapy of bladder cancer. However it may have, as adverse event, a reactive arthritis (ReA)…
Abstract Number: 2817 • 2015 ACR/ARHP Annual Meeting
The Microbiome of Reactive Arthritis in a Guatemalan Cohort
Alexis Ogdie-Beatty¹, Carles Ubeda², Helga Raquel Garcia Ferrer³, Joan Von Feldt⁴, A Garcia Kutzbach⁵ and Jose U. Scher⁶, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Institute for Research in Public Health, Valencia, Spain, ³Society for Worldwide Med Exchange, North Bay Village, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Internal Medicine, Rheumatology Unit (AGAR), Francisco Marroquin University, School of Medicine, Guatemala City, Guatemala, ⁶Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Reactive arthritis (ReA) is an inflammatory arthritis that typically follows infection. Several agents microbial agents have been implicated, particularly Shigella, Salmonella, Campylobacter in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].